Update in lung transplantation 2008

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 9, 2009, Pages 759-764

  Lama, Vibha N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ADENOSINE A2A RECEPTOR AGONIST; ATL 313; AZITHROMYCIN; CURCUMIN; INCYCLINIDE; INTERLEUKIN 13; INTERLEUKIN 17; METALLOPROTEINASE INHIBITOR; THIOREDOXIN 1; THROMBOMODULIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; BRONCHIOLITIS OBLITERANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; EPSTEIN BARR VIRUS; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SURVIVAL; ARTICLE; GRAFT DYSFUNCTION; GRAFT REJECTION; LUNG DISEASE; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; REOPERATION; RISK FACTOR;

BRONCHIOLITIS OBLITERANS; GRAFT REJECTION; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PRIMARY GRAFT DYSFUNCTION; REOPERATION; RISK FACTORS;

EID: 65549137981     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200902-0177UP     Document Type: Review

References (58)

1. Corris PA, Christie JD. Update in transplantation 2007. Am J Respir Crit Care Med 2008;177:1062-1067.
2. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, Taylor DO, Kucheryavaya AY, Hertz MI. Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplantation report - 2008. J Heart Lung Transplant 2008;27:957-969.
3. Lederer DJ, Benn EK, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:450-454.
4. Thabut G, Christie JD, Ravaud P, Castier Y, Brugiere O, Fournier M, Mal H, Leseche G, Porcher R. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008;371:744-751.
5. Thabut G, Ravaud P, Christie JD, Castier Y, Fournier M, Mal H, Leseche G, Porcher R. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1156-1163.
6. Murray S, Kawut S. Defining transplantation and listing benefit in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:1054-1055.
7. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008;178:363-371.
8. Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation 2008;85:547-553.
9. McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008;27:1203-1209.
10. Gregson AL, Hoji A, Saggar R, Ross DJ, Kubak BM, Jamieson BD, Weigt SS, Lynch JP III, Ardehali A, Belperio JA, et al. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation 2008;85:1056-1059.
11. Patil J, Lande JD, Li N, Berryman TR, King RA, Hertz MI. Bronchoalveolar lavage cell gene expression in acute lung rejection: development of a diagnostic classifier. Transplantation 2008;85:224-231.
12. Jarvinen L, Badri L, Wettlaufer S, Ohtsuka T, Standiford TJ, Toews GB, Pinsky DJ, Peters-Golden M, Lama VN. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 2008;181:4389-4396.
13. Hartwig MG, Snyder LD, Appel JZ III, Cantu E III, Lin SS, Palmer SM, Davis RD. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008;27:547-553.
14. Kozower BD, Meyers BF, Smith MA, De Oliveira NC, Cassivi SD, Guthrie TJ, Wang H, Ryan BJ, Shen KR, Daniel TM, et al. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. J Thorac Cardiovasc Surg 2008;135:166-171.
15. McCue JD, Mooney J, Quail J, Arrington A, Herrington C, Dahlberg PS. Ninety-day mortality and major complications are not affected by use of lung allocation score. J Heart Lung Transplant 2008;27:192-196.
16. Bobadilla JL, Love RB, Jankowska-Gan E, Xu Q, Haynes LD, Braun RK, Hayney MS, Munoz del Rio A, Meyer K, Greenspan DS, et al. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 2008;177:660-668.
17. Iwata T, Philipovskiy A, Fisher AJ, Presson RG Jr, Chiyo M, Lee J, Mickler E, Smith GN, Petrache I, Brand DB, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008;181:5738-5747.
18. Westall GP, Snell GI, McLean C, Kotsimbos T, Williams T, Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008;27:722-728.
19. Oto T, Excell L, Griffiths AP, Levvey BJ, Bailey M, Marasco S, Macdonald P, Snell GI. Association between primary graft dysfunction among lung, kidney and heart recipients from the same multi-organ donor. Am J Transplant 2008;8:2132-2139.
20. Anraku M, Cameron MJ, Waddell TK, Liu M, Arenovich T, Sato M, Cypel M, Pierre AF, de Perrot M, Kelvin DJ, et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008;8:2140-2148.
21. Daud SA, Yusen RD, Meyers BF, Chakinala MM, Walter MJ, Aloush AA, Patterson GA, Trulock EP, Hachem RR. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007;175:507-513. (Pubitemid 46354255)
22. Huang HJ, Yusen RD, Meyers BF, Walter MJ, Mohanakumar T, Patterson GA, Trulock EP, Hachem RR. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008;8:2454-2462.
23. Bharat A, Kuo E, Steward N, Aloush A, Hachem R, Trulock EP, Patterson GA, Meyers BF, Mohanakumar T. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008;86:189-195. [Discussion 196-187.]
24. Amital A, Shitrit D, Raviv Y, Saute M, Medalion B, Bakal L, Kramer MR. The use of surfactant in lung transplantation. Transplantation 2008;86:1554-1559.
25. Amital A, Shitrit D, Raviv Y, Saute M, Bakal I, Medalion B, Kramer MR. Surfactant as salvage therapy in life threatening primary graft dysfunction in lung transplantation. Eur J Cardiothorac Surg 2008;35:299-303.
26. Egemnazarov B, Sydykov A, Schermuly RT, Weissmann N, Stasch JP, Sarybaev AS, Seeger W, Grimminger F, Ghofrani HA. Novel soluble guanylyl cyclase stimulator bay 41-2272 attenuates ischemia/reperfusion induced lung injury. Am J Physiol Lung Cell Mol Physiol 2008;296:L462-L469.
27. Kohmoto J, Nakao A, Sugimoto R, Wang Y, Zhan J, Ueda H, McCurry KR. Carbon monoxide-saturated preservation solution protects lung grafts from ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2008;136:1067-1075.
28. Hu H, Lu L, Mu W, Johnson RJ, Block ER, Patel JM. Priming donor lungs with thioredoxin-1 attenuates acute allograft injury in a rat model of lung transplantation. J Heart Lung Transplant 2008;27:1142-1149.
29. Sun J, Yang D, Li S, Xu Z, Wang X, Bai C. Effects of curcumin or dexamethasone on lung ischemia-reperfusion injury in rats. Eur Respir J 2009;33:398-404.
30. Geudens N, Van de Wouwer M, Vanaudenaerde BM, Vos R, Van De Wauwer C, Verleden GM, Verbeken E, Lerut T, Van Raemdonck DE, Conway EM. The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury. Eur Respir J 2008;32:862-870.
31. Iwata T, Chiyo M, Yoshida S, Smith GN Jr, Mickler EA, Presson R Jr, Fisher AJ, Brand DD, Cummings OW, Wilkes DS. Lung transplant ischemia reperfusion injury: metalloprotease inhibition down-regulates exposure of type V collagen, growth-related oncogene-induced neutrophil chemotaxis, and tumor necrosis factor-alpha expression. Transplantation 2008;85:417-426.
32. Garcia-Covarrubias L, Manning EW III, Sorell LT, Pham SM, Majetschak M. Ubiquitin enhances the Th2 cytokine response and attenuates ischemia-reperfusion injury in the lung. Crit Care Med 2008;36:979-982.
33. Gazoni LM, Laubach VE, Mulloy DP, Bellizzi A, Unger EB, Linden J, Ellman PI, Lisle TC, Kron IL. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg 2008;135:156-165.
34. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996;15:1-15.
35. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med 2008;177:1033-1040.
36. Burton CM, Iversen M, Scheike T, Carlsen J, Andersen CB. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008;27:1128-1134.
37. Studer SM, George MP, Zhu X, Song Y, Valentine VG, Stoner MW, Sethi J, Steele C, Duncan SR. CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients. Am J Respir Crit Care Med 2008;178:765-773.
38. Xu J, Torres E, Mora AL, Shim H, Ramirez A, Neujahr D, Brigham KL, Rojas M. Attenuation of obliterative bronchiolitis by a CXCR4 antagonist in the murine heterotopic tracheal transplant model. J Heart Lung Transplant 2008;27:1302-1310.
39. Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 2008;31:1037-1045.
40. Botha P, Archer L, Anderson RL, Lordan J, Dark JH, Corris PA, Gould K, Fisher AJ. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008;85:771-774.
41. Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, Sloots T, Nissen M. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008;178:876-881.
42. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, Boehler A. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008;46:831-839.
43. Lama VN, Murray S, Lonigro RJ, Toews GB, Chang A, Lau C, Flint A, Chan KM, Martinez FJ. Course of FEV1 after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007;175:1192-1198. (Pubitemid 46855462)
44. Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, Weder W, Boehler A. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation 2008;86:1625-1627.
45. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008;85:36-41.
46. Nathan SD, Shlobin OA, Ahmad S, Barnett SD, Burton NA, Gladwin MT, Machado RF. Pulmonary hypertension in patients with bronchiolitis obliterans syndrome listed for retransplantation. Am J Transplant 2008;8:1506-1511.
47. Saggar R, Ross DJ, Saggar R, Zisman DA, Gregson A, Lynch JP III, Keane MP, Weigt SS, Ardehali A, Kubak B, et al. Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft. Am J Transplant 2008;8:1921-1930.
48. Meloni F, Solari N, Miserere S, Morosini M, Cascina A, Klersy C, Arbustini E, Pellegrini C, Vigano M, Fietta AM. Chemokine redundancy in BOS pathogenesis. A possible role also for the CC chemokines: MIP3-β, MIP3-α, MDC and their specific receptors. Transpl Immunol 2008;18:275-280.
49. Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, Ardehali A, Gregson AL, Kubak B, Fishbein MC, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008;8:1512-1522.
50. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reynders V, Wuyts WA, Van Raemdonck DE, Dupont LJ, Verleden GM. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2008;8:1911-1920.
51. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-α1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008;180:4487-4494.
52. Sato M, Liu M, Anraku M, Ogura T, D'Cruz G, Alman BA, Waddell TK, Kim E, Zhang L, Keshavjee S. Allograft airway fibrosis in the pulmonary milieu: a disorder of tissue remodeling. Am J Transplant 2008;8:517-528.
53. Hollmen M, Tikkanen JM, Nykanen AI, Koskinen PK, Lemstrom KB. Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. J Heart Lung Transplant 2008;27:856-864.
54. Remund K, Rechsteiner T, Rentsch K, Vogt P, Russi EW, Boehler A. Attenuation of airway obliteration by ciprofloxacin in experimental posttransplant bronchiolitis obliterans. Transplantation 2008;85:726-731.
55. KleinJan A, Willart MA, Kuipers H, Coyle AJ, Hoogsteden HC, Lambrecht BN. Inducible costimulator blockade prolongs airway luminal patency in a mouse model of obliterative bronchiolitis. Transplantation 2008;86:1436-1444.
56. Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris RM. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med 2008;178:1060-1065.
57. Kawut SM, Lederer DJ, Keshavjee S, Wilt JS, Daly T, D'Ovidio F, Sonett JR, Arcasoy SM, Barr ML. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008;177:114-120.
58. Aigner C, Jaksch P, Taghavi S, Lang G, Reza-Hoda MA, Wisser W, Klepetko W. Pulmonary retransplantation: Is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008;27:60-65.